Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 + KL-A167 neoadjuvant therapy for high‑risk ER+/HER2‑ early breast cancer
ChiCTR2500108090Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and tagitanlimab in breast cancer, sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological Complete Response (pCR) Rate (ypT0/Tis ypN0). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantagitanlimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500108090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108090.